Related Experiment Video
Updated: May 21, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice]
Junming Peng1, Xiaojun Shi, Dingnan Chen
1Department of Urinary Surgery, Southern Medical University, Guangzhou, China. pjmap@126.com
Objective:
To develop a novel vaccine by immobilizing interleukin-21 (IL-21) on the surface of MB49 cells and evaluate its effect in inducing specific cytotoxic T lymphocytes (CTLs) and antitumor immunity in a mouse model of subcutaneous metastatic bladder cancer.
Methods:
SA-IL-21 was immobilized on the surface of 30% ethanol-fixed MB49 cells to prepare the cell vaccine. C57BL/6 mice with subcutaneous implantation of MB49 bladder cancer cells were randomized into 5 groups to receive treatments with IL-21/MB49 vaccine, soluble IL-21, GFP surface-modified MB49 cells, ethanol-fixed MB49 cells, or PBS. The tumor growth and CTL were examined to assess the antitumor efficacy of the vaccine.
Results:
IL-21 surface-modified MB49 cell vaccine significantly inhibited the tumor growth and generated a long-lasting memory response (P<0.05). At the same effector-target (E:T) ratio, the specific CTLs induced by IL-21/MB49 vaccine showed the most potent cytotoxicity against MB49 cells (P<0.05).
Conclusion:
With the protein-anchor technique, IL-21 can be efficiently immobilized on the surface of MB49 cells to prepare IL-21/MB49 cells vaccine. The novel vaccine can maintain its biological activity and significantly enhance the cytotoxicity of CTLs against bladder cancer cells.
Insights
A novel bladder cancer vaccine immobilizing interleukin-21 (IL-21) on MB49 cells effectively inhibits tumor growth. This vaccine induces potent cytotoxic T lymphocytes (CTLs) and establishes a lasting antitumor memory response.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Bladder cancer remains a significant health concern, necessitating novel therapeutic strategies.
- Cytotoxic T lymphocytes (CTLs) play a crucial role in antitumor immunity.
- Interleukin-21 (IL-21) is a cytokine with known immunomodulatory properties relevant to cancer therapy.
Purpose of the Study:
- To develop and evaluate a novel cell-based vaccine by immobilizing IL-21 onto MB49 bladder cancer cells.
- To assess the vaccine's ability to induce specific CTL responses and antitumor immunity.
- To investigate the efficacy of the IL-21/MB49 vaccine in a murine model of subcutaneous metastatic bladder cancer.
Main Methods:
- SA-IL-21 was immobilized on ethanol-fixed MB49 cells to create the IL-21/MB49 vaccine.
- C57BL/6 mice bearing MB49 tumors were randomized into treatment groups (IL-21/MB49 vaccine, soluble IL-21, control cells, PBS).
- Tumor growth and CTL activity were monitored to determine antitumor efficacy.
Main Results:
- The IL-21/MB49 vaccine significantly inhibited tumor growth compared to control groups (P<0.05).
- A long-lasting memory response was observed following vaccination.
- The vaccine induced specific CTLs with potent cytotoxicity against MB49 cells at equivalent effector-target ratios (P<0.05).
Conclusions:
- A protein-anchor technique efficiently immobilizes IL-21 on MB49 cells, creating a viable vaccine.
- The novel IL-21/MB49 vaccine demonstrates preserved biological activity.
- This approach significantly enhances CTL-mediated cytotoxicity against bladder cancer cells, offering a promising therapeutic strategy.
